Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
CCR5 antagonists might be an adequate alternative for HIV-1-infected individuals with
suppressed viremia who experience antiretroviral-related toxicity. The assessment of HIV-1
tropism in proviral DNA could be helpful to inform in which of these subjects CCR5
antagonists could be efficacious.
Phase:
Phase 4
Details
Lead Sponsor:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia